Dr. Hackett as the new CRC Tier 1 Chair in Asthma and COPD Lung Pathobiology & Therapeutics

Congratulations to Dr. Tillie-Louise Hackett who was awarded a Tier 1 Canada Research Chair in Asthma and COPD Lung Pathobiology & Therapeutics and Canadian Foundation for Innovation Funding for Single Cell Imaging Research.

In Canada, over 5.8 million people have asthma and chronic obstructive pulmonary disease (COPD) – diseases for which there is no cure – that make it challenging every day to breathe.
Dr. Tillie Hackett’s research uses ultra-resolution imaging to identify lung disease at its earliest stages that cannot be detected using current clinical tests, to define the cellular and molecular alterations responsible for the disease pathobiology. This research will enable a better understanding of how these lung diseases develop, providing new approaches for prediction and diagnosis, resulting in new treatments to improve the lives of asthma and COPD patients.

https://hackettlab.med.ubc.ca
https://www.hli.ubc.ca/researchers/tillie-hackett/

UBC ANNOUNCEMENT
https://research.ubc.ca/fifteen-new-and-renewed-ubc-canada-research-chairs-announced

GOVERNMENT OF CANADA ANNOUNCEMENT
https://www.canada.ca/en/innovation-science-economic-development/news/2021/06/government-of-canada-makes-major-investment-in-canadian-science-research-and-engineering.html

CRC ANNOUNCEMENT
https://www.chairs-chaires.gc.ca/media-medias/lists-listes/2021/june-juin-eng.aspx